Who Paid My Doc
Mark Russo
Transplant Hepatology Greensboro, NC Medical Doctor
NPI 1588745392 CMS profile 207501
1126 N Church St, Ste 201, Greensboro, NC 27401
General payments
$113,424
Research payments
$2,300
Ownership & investment interest
$0
Research they led as principal investigator
$12,366
Through program year 2025, Mark Russo of Greensboro, NC is reported in the CMS Open Payments database as having received $113,424 across 113 general payments and $2,300 in research payments paid to them. Separately, studies naming them as principal investigator received $12,366 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 89th percentile of Transplant Hepatology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
9 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $6,666 | 11 | |
| 2024 | General | $781 | 3 | |
| 2023 | General | $3,522 | 4 | |
| 2022 | General | $666 | 7 | |
| 2022 | Research | $700 | 4 | |
| 2021 | General | $98 | 1 | |
| 2021 | Research | $1,600 | 1 | |
| 2020 | General | $2,260 | 7 | |
| 2019 | General | $99,432 | 80 |
Beside peers
- Mark Russo
- Transplant Hepatology median
- Middle half of Transplant Hepatology
- National median
In program year 2025, general payments to Mark Russo were reported at $6,666. Among 195 Transplant Hepatology profiles paid that year, the median was $499 and the middle half received between $124 and $5,839.
Show as a table
| Year | Mark Russo | Transplant Hepatology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $99,432 | $386 | $98–$3,771 | $163 |
| 2020 | $2,260 | $445 | $42–$8,101 | $114 |
| 2021 | $98 | $262 | $82–$3,660 | $132 |
| 2022 | $666 | $323 | $125–$3,034 | $149 |
| 2023 | $3,522 | $289 | $96–$3,037 | $160 |
| 2024 | $781 | $409 | $110–$6,270 | $164 |
| 2025 | $6,666 | $499 | $124–$5,839 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 20 drugsPart D claims
1,111
Drug cost
$621,410
Branded share of claims
16.9%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Ocaliva Obeticholic Acid | Brand | 35 | $316,533 | |
| Xifaxan Rifaximin | Brand | 57 | $179,170 | |
| Ursodiol | Generic | 251 | $33,991 | |
| Tacrolimus | Generic | 215 | $28,747 | |
| Mycophenolic Acid Mycophenolate Sodium | Brand | 41 | $19,952 | |
| Envarsus Xr Tacrolimus | Brand | 11 | $14,413 | |
| Entecavir | Generic | 49 | $7,154 | |
| Mycophenolate Mofetil | Generic | 72 | $6,276 | |
| Cyclosporine Modified Cyclosporine, Modified | Brand | 25 | $4,721 | |
| Sirolimus | Generic | 25 | $4,471 |
The 10 drugs with the highest cost, of 20 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 22 billing codesPaid by Medicare
$18,910
Medicare patients
199
Services billed
308
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 48% | |
| Diabetes | 38% | |
| Chronic kidney disease | 38% | |
| Ischemic heart disease | 24% | |
| Depression | 21% | |
| Osteoporosis | 19% | |
| COPD | 16% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
118 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Transplant Hepatology in North Carolina
Andrew Delemos
Transplant Hepatology · Charlotte, NC
Neil Shah
Transplant Hepatology · Chapel Hill, NC
Dianna Howard
Transplant Hepatology · Winston Salem, NC
Natasha Adlakha
Transplant Hepatology · Huntersville, NC
Sasha Deutsch-Link
Transplant Hepatology · Chapel Hill, NC
Paul Schmeltzer
Transplant Hepatology · Charlotte, NC
Related records
Transplant Hepatology in North Carolina
Practitioners in the same specialty and state, ranked by reported value.
All Transplant Hepatology
Everyone recorded under this specialty, nationwide.
Doctors in North Carolina
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.